Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03270098 · ClinicalTrials.gov registry record · NA

Improving Cognition Via Exercise in Schizophrenia

A NA study, sponsored by Icahn School of Medicine at Mount Sinai.

Completed
Registry status
NA
Development phase
104
Enrollment target

NCT03270098: Completed NA study, sponsored by Icahn School of Medicine at Mount Sinai.

NCT03270098 is a NA study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 104 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03270098, a NA study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.

COMPLETED
Registry status
NA
Development phase
104 participants
Enrollment target

Study Summary

People with schizophrenia display a broad range of cognitive impairments that have been identified as major determinants of poor functioning and disability. Also, people with schizophrenia are at increased risk for suicide, with approximately 40-50% of individuals attempting to take their own lives during their lifetime. The goal of the proposed study is to examine the impact of remote exercise training on cognition, suicide risk, daily functioning, and biomarkers of cognitive change and suicidality in people with schizophrenia.

Primary Outcome

The MCCB is a standardized battery designed to measure cognitive functioning in people with schizophrenia. The MCCB is represented as a composite T score. Change in the MCCB at 12 weeks as compared to baseline.

Interventions

  • BEHAVIORAL Aerobic Exercise
  • BEHAVIORAL Stretching and Toning Exercise

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2018-04-26
Est. Completion 2023-01-31
Phase NA

What the finished NCT03270098 record still lists

NCT03270098 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 2 interventions - of which Aerobic Exercise is the first listed.

NCT03270098 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03270098 about?

NCT03270098 is a clinical study titled "Improving Cognition Via Exercise in Schizophrenia". People with schizophrenia display a broad range of cognitive impairments that have been identified as major determinants of poor functioning and disability. Also, people with schizophrenia are at increased risk for suicide, with approximately 40-50% of individuals attempting to take their own lives ...

What is the current status of trial NCT03270098?

This trial is currently completed. It is a NA study. The enrollment target is 104 participants. The study started on 2018-04-26. Estimated completion is 2023-01-31.

What interventions are being tested in trial NCT03270098?

The interventions under investigation include: Aerobic Exercise (BEHAVIORAL), Stretching and Toning Exercise (BEHAVIORAL).

Who is sponsoring clinical trial NCT03270098?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03270098's enrollment target sits among peer trials

104 836th of 2000 higher than 1,164 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03403686 · 104 participants

    Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

  • NCT04228367 · 104 participants · NA

    JuggerStitch Post Market Clinical Follow-up Study

  • NCT04268849 · 104 participants · Phase 3

    Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

  • NCT04390724 · 104 participants

    Optimizing Y90 Therapy for Radiation Lobectomy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03270098, the US trial registry maintained by the National Library of Medicine. NCT03270098 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.